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several other promising candidate genes, including
neuregulin-1 and dysbindin.12 Interestingly,
neuregulin-1 and dysbindin proteins are known to
have important roles in neurodevelopment and
synaptic functions, like DISC-1.
In addition to deficits in neural development, several
aspects of the pathogenesis of schizophrenia have been
studied, including dysfunctions of glutamatergic and
dopaminergic neurotransmission. Possible environmen-
tal factors superimposed on genetic vulnerability
include virus infection as well as gestational and birth
complications. By studying genetically engineered mice
with susceptibility factors such as DISC-1 in combina-
tion with environmental stresses, it may be possible to
provide a more definitive, integrated model for the
pathogenesis of schizophrenia in the future.
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Partner notification for the control of sexually
transmitted infections
Effectiveness in resource poor countries is unproved
Partner notification (also termed partner man-agement or contact tracing in some settings) is awell established public health activity in pro-
grammes to control sexually transmitted infection.1
The approach is based on the premise that the sexual
partners of people with sexually transmitted infections
are likely to be infected but may be asymptomatic and
may not otherwise seek care. Partners can be reached
through several different strategies including those led
by infected “index” patients (patient led), by health
providers (provider led), or by a combination of
approaches (conditional referral—index patients are
encouraged to ensure that partners attend by an
agreed date, after which the provider will notify the
partner). The public health objectives of each of these
strategies are the same: to increase the coverage of care
of sexually transmitted infections—by identifying and
when necessary treating those people known to be at
high risk for sexually transmitted infections 2; to inter-
rupt the cycle transmission of infection; and to reduce
the incidence of new infections and the overall burden
of disease. This is the theory. In practice, do partner
notification strategies work?
The evidence for the effectiveness of strategies for
partner notification has recently been reviewed.3 This
systematic Cochrane review is the first to include stud-
ies of partner notification in low income countries—an
economic definition, but one that includes many coun-
tries where sexually transmitted infections contribute
substantially to the overall burden of adult disease.4
The authors of the review found 11 randomised
controlled trials, which compared two or more
strategies for partner notification, and only two of
these studies had been undertaken in poor countries,
both of them in southern Africa. This imbalance raises
questions about transferring study findings (and by
implication conclusions and recommendations for
policies and programmes) to settings far different from
those where the original research was undertaken—a
concern raised by the authors of the review.
The systematic review concluded that provider led
referral (or a choice between patient led and provider
led referral) is more likely to result in partners present-
ing for medical care than patient led referral, and that
conditional referral for patients with gonorrhoea is
more effective than patient led referral. In addition a
slight increase in partners treated was seen in one
study, which used nurse led health education and lay
counselling as the intervention.
What are the resource and programmatic implica-
tions of these findings for public sector health systems
in settings that are poor in resources—those, for exam-
ple, struggling to provide adequate care and attention
in an average of well under five minutes per patient?
Will providers in such settings really have time to
undertake the steps needed to ensure that partner
referral programmes are successful? Given the myriad
competing concerns on health budgets, are partner
notification interventions for sexually transmitted
infections likely to be cost effective? Moreover, what are
the implications of implementing either provider led
or patient led referral programmes in settings of widely
different cultural, social, and economic environments
from the ones where most studies are undertaken—
settings where, for example, there will be highly differ-
ential rates of power in sexual relationships5 or a risk of
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gender based violence?6 Should strategies found to be
(just) effective in one type of setting be so easily recom-
mended in an entirely different milieu?
Concerns over the feasibility and effectiveness of
partner notification for sexually transmitted infections
in resource poor settings are compounded by the rela-
tive lack of specificity of many diagnoses of sexually
transmitted infections in these settings. In the absence
of highly sensitive and specific diagnostic tools at low
cost, providers rely on approaches that may result in
relatively high levels of overdiagnosis of sexually trans-
mitted infections, especially in women.7 Although these
approaches may sometimes be justified in public
health terms, should they be the basis for recommend-
ing management of partners if we are not sure that the
individual known as the index patient is truly infected?
Partner notification has come a long way since its
inception in the 19th century but has much further to
go in terms of knowing what is effective in resource
poor settings. While many studies concentrate on the
issue of effectiveness before considering allocation of
resources, it is time to build on the findings of this
review and carry out methodologically sound trials to
determine what is appropriate and acceptable to indi-
viduals in a variety of resource poor communities. This
should be the first step in deciding whether partner
notification is justified for programmes to control
sexually transmitted infections globally.
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Immunomodulatory drugs for psoriasis
New “biologics” offer much promise
With a prevalence of 2-3%, psoriasis is amongthe most common skin diseases. Clinicalhallmarks comprise erythematous plaques
covered by silvery scaling and a chronic recurrent
course. Psoriasis is now considered an autoimmune dis-
ease in which antigen presentation to cutaneous T
helper cells triggers secretion of cytokines, causing pro-
liferation of keratinocytes and expression of adhesion
molecules on endothelial cells. These attract additional
effector T cells from the circulation, which are then acti-
vated in an antigen specific manner, leading to secretion
of more cytokines and perpetuation of the process.1
Although topical treatments are sufficient for many
patients, about 20% need additional systemic drugs. All
of these bear a considerable potential for serious side
effects, such as hepatotoxicity and nephrotoxicity
(methotrexate, cyclosporine),2 3 teratogenicity (oral
retinoids),4 and cancer (PUVA, which is psoralen and
long wave ultraviolet radiation; cyclosporine),5 6 which
limits their long term use. The limitations of treatments
on the one hand and a growing understanding of the
pathogenesis of psoriasis on the other have stimulated
much interest in the field of immunomodulation for
the management of this chronic disease.
Earlier this year the US Food and Drug
Administration approved alefacept for use in psoriasis.
Alefacept interferes with the activation of T lym-
phocytes by blocking the co-stimulator CD2 molecule.
It also mediates T cell elimination by inducing
programmed cell death. Both mechanisms are believed
to contribute to the drug’s clinical effectiveness.7 The
availability of alefacept is a major breakthrough in
medical and immunological terms. Not only does it
prove clinical effectiveness of a strategy rationally
deduced from insights in lymphocyte biology at the
molecular level, but many contraindications for
established systemic treatments do not apply to
alefacept, which facilitates its clinical use.
Alefacept can be regarded as the pioneer of a novel
class of selective immunomodulatory drugs for the
treatment of psoriasis. Since these are either naturally
occurring molecules, such as antibodies and cytokines,
or modifications thereof, such as soluble receptors or
fusion proteins (as in the case of alefacept), they are
referred to as biologics. Well over 40 such compounds
are being developed for psoriasis, some of which have
already been approved by the Food and Drug Adminis-
tration for other chronic inflammatory diseases medi-
ated by T lymphocytes—for example, rheumatoid
arthritis. Given the very similar pathogenesis of these
conditions at the molecular level, several of these drugs
may prove effective in the management of psoriasis. Evi-
dence supporting this notion is available for infliximab
and etanercept, which are both approved for rheuma-
toid arthritis. These biologics block the effect of the pro-
inflammatory cytokine tumour necrosis factor-
(TNF-) and exhibit profound effects on psoriasis.8 9 Inf-
liximab is a humanised monoclonal antibody, whereas
etanercept represents the soluble tumour necrosis
factor- receptor. All three drugs allow moderate to
severe psoriasis to be managed on an outpatient basis,
since they are administered once (alefacept) or twice
weekly (etanercept), or just three times overall with inter-
vals of several weeks (infliximab). This convenient dosing
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